Document is current
Any future updates will be listed below
-
Authors
Deliu, Nina https://orcid.org/0000-0003-2501-8795
Das, Rajenki
May, Angelique
Newman, Joseph
Steele, Jo
Duckworth, Melissa
Jones, Rowena J.
Wilkins, Martin R.
Toshner, Mark R.
Villar, Sofia S.
- License Information
-
More Information
Article History
Received: 27 September 2023
Accepted: 19 September 2024
First Online: 15 October 2024
Declarations
:
: Ethical approval was gained from London Surrey Borders on date 12/09/2023. Written, informed consent will be obtained from all participants. A copy of the informed consent document is available as a supplemental file.
: Not applicable: there are no data or details on individuals reported within the manuscript.
: Authors of this paper have been part of advisory boards and safety committees for PhaseV, MorphogenIX, VIVUS, Janssen, Acceleron, GSK, Novartis, ComCov and, FluCov. Are disclosed consultancies to Cheisi, Aerami, Benevolent AI, Jansen, Apollo Therapeutics and, Merck. Travel support has been received from Aparito Ltd, United Therapeutics, Apollo Therapeutics, GSK, Jansen and, Pulmonary Vascular Research Institute.
